Aldesleukin
- Generic Name
- Aldesleukin
- Brand Names
- Proleukin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 110942-02-4
- Unique Ingredient Identifier
- M89N0Q7EQR
- Background
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native in...
- Indication
For treatment of adults with metastatic renal cell carcinoma.
- Associated Conditions
- Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
- Associated Therapies
- -
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics granted 203,980 stock options to 48 new non-executive employees on Dec 19, 2024, under its Amended and Restated 2021 Inducement Plan. Each option has an exercise price of $7.22 and vests over three years.
Iovance Biotherapeutics Reports Financial Results and
Iovance Biotherapeutics reports $58.6M in 3Q24 product revenue for Amtagvi™ (Lifileucel), reaffirming $160-$165M FY24 and $450-$475M FY25 guidance. European regulatory authorities validate and accept marketing authorization applications for potential approval starting in 1H2025 for the UK and 2H2025 for EU and Canada. Enrollment accelerates in IOV-LUN-202 Phase 2 trial in post-anti-PD-1 NSCLC.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath